Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate + chidamide + azacitidine in newly diagnosed peripheral T-cell lymphoma
ChiCTR2500109351Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pralatrexate, tucidinostat and azacitidine in peripheral T-cell lymphoma (PTCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Progression-free survival and Safety. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
pralatrexatetucidinostatazacitidine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2500109351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109351.